Yes, Reyvow (lasmiditan) is a controlled substance. It is classified as a Schedule V drug under the Controlled Substances Act, which is the lowest level of federal scheduling. The Drug Enforcement Administration finalized this placement on May 24, 2021. This means your pharmacy will handle it differently than a typical prescription medication, and it carries certain legal requirements around how it’s prescribed and dispensed.
Why Reyvow Is Scheduled
Reyvow works by activating serotonin receptors in the brain to stop migraine attacks. Unlike triptans, which target blood vessels, Reyvow primarily targets a specific serotonin receptor involved in pain signaling. But the drug also crosses into the central nervous system and interacts with receptors associated with sedation and mood alteration, which raised concerns about misuse during the FDA review process.
In animal studies, rats given access to lasmiditan self-administered the drug at rates higher than a placebo, similar to the sedative diazepam (though not as high as heroin). In a human abuse potential study, every tested dose of Reyvow produced significantly higher “drug liking” scores than a placebo. During broader clinical trials, abuse-related side effects occurred more often with Reyvow than with placebo, though at a low rate of about 1% of patients. Based on all of this, both the drugmaker and FDA reviewers agreed that Schedule V was the appropriate classification.
What Schedule V Means in Practice
Schedule V is the least restrictive controlled substance category. For context, it sits below Schedule IV drugs like benzodiazepines and sleep medications, and well below Schedule II drugs like opioid painkillers. Other Schedule V substances include certain cough preparations containing small amounts of codeine.
In practical terms, Reyvow requires a prescription for a legitimate medical purpose, and your pharmacy must track it as a controlled substance. Some pharmacies may need a day or two to order it if they don’t stock it regularly. Your state may have additional rules beyond the federal requirements, so filling procedures can vary depending on where you live. Federal law does not impose the same strict refill limits on Schedule V drugs that apply to Schedule III and IV medications, but your prescriber will still set a specific refill plan.
Side Effects That Led to Scheduling
The reason Reyvow ended up scheduled has a lot to do with how it makes people feel. The drug’s most common side effect is dizziness, which affected 15% of patients taking the 100 mg dose and 17% taking 200 mg in two major clinical trials (SAMURAI and SPARTAN). A later trial (CENTURION) found even higher rates: 22% at 100 mg and 27% at 200 mg.
Sedation and drowsiness are also significant. In clinical trials, 6% to 8% of patients reported sedation depending on the dose. Tingling or numbness (paresthesia) affected 7% to 15% of patients at the higher doses. These central nervous system effects are the same properties that give Reyvow its abuse potential, since some people may find the sedation or altered sensation pleasurable.
The 8-Hour Driving Restriction
One of the most important practical consequences of Reyvow’s brain effects is a strict warning against driving for at least 8 hours after taking a dose. In a simulated driving study, Reyvow caused dose-dependent impairment when tested 90 minutes after administration. A follow-up study found that driving ability returned to acceptable levels at the 8-hour mark, which is how the FDA settled on that threshold.
What makes this particularly tricky is that participants in the study couldn’t accurately judge their own impairment. When asked whether they felt safe to drive, their self-assessments didn’t match their actual driving performance. This means you shouldn’t rely on how you feel to decide whether it’s safe to get behind the wheel. The 8-hour rule applies every time you take Reyvow, regardless of whether you feel fine afterward.
How This Affects You as a Patient
If your doctor prescribes Reyvow, the controlled substance classification mostly affects logistics rather than your ability to get the medication. You’ll need a valid prescription each time, and some insurance plans may require prior authorization since it’s both a newer brand-name drug and a controlled substance. Your pharmacy will log each fill in a prescription drug monitoring program, which is standard for all controlled substances.
The scheduling doesn’t mean Reyvow is dangerous when used as directed. It reflects the FDA’s recognition that the drug has some potential for misuse, even if that potential is low. For many migraine patients, especially those who can’t take triptans due to cardiovascular risks, Reyvow fills an important gap in treatment. The key is planning around the side effects: take it when you can avoid driving for 8 hours, and be aware that dizziness and drowsiness are common, not rare.